Department of Neurology, NorthShore University HealthSystem, Glenview, IL.Disease-a-month: DM (Impact Factor: 0.54). 12/2012; 58(12):666-677. DOI: 10.1016/j.disamonth.2012.08.008
[Show abstract] [Hide abstract]
- "No accepted biomarker for Alzheimer's disease exists, and this disease can only by diagnosed by brain biopsy or autopsy clinics. The key issue in the current study was to improve the accuracy of clinical diagnosis of Alzheimer's disease and to improve the sensitivity of early diagnosis of this disease. "
ABSTRACT: 3.0T magnetic resonance spectroscopic imaging is a commonly used method in the research of brain function in Alzheimer's disease. However, the role of 7.0T high-field magnetic resonance spectroscopic imaging in brain function of Alzheimer's disease remains unclear. In this study, 7.0T magnetic resonance spectroscopy showed that in the hippocampus of Alzheimer's disease rats, the N-acetylaspartate wave crest was reduced, and the creatine and choline wave crest was elevated. This finding was further supported by hematoxylin-eosin staining, which showed a loss of hippocampal neurons and more glial cells. Moreover, electron microscopy showed neuronal shrinkage and mitochondrial rupture, and scanning electron microscopy revealed small size hippocampal synaptic vesicles, incomplete synaptic structure, and reduced number. Overall, the results revealed that 7.0T high-field nuclear magnetic resonance spectroscopy detected the lesions and functional changes in hippocampal neurons of Alzheimer's disease rats in vivo, allowing the possibility for assessing the success rate and grading of the amyloid beta (1-40) animal model of Alzheimer's disease.Neural Regeneration Research 02/2014; 9(4):430-5. DOI:10.4103/1673-5374.128255 · 0.23 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.